RKDA Company Profile and Key Details

Arcadia Biosciences, Inc. (NASDAQ:RKDA) closed at $0.68 USD, losing -$0.01 (-1.14%) from the previous close of $0.68. The stock is currently mid-range between its 52-week high and low $0.63 and $6.71. With a market capitalization of about $1.05 million, Arcadia Biosciences, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.54). Key stats such as the average daily volume over the past year has been around 3.14 million shares, volume is running light vs its 52-week average. Headquartered in Davis, TX, Arcadia Biosciences, Inc. operates in the Basic Materials sector and the Agricultural Inputs industry. Led by CEO Thomas J. Schaefer, the company employs approximately 9 people and listed since May 15, 2015. Arcadia Biosciences, Inc. is a U.S.-based company that provides plant-derived health and well-being products.

Short-term trend indicators are bullishly aligned (SMA20 6.69%, SMA50 -15.04%, SMA200 -45.99%). The stock’s 14-day RSI is 48.44 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -70.64% below its high and over 27.92% above its low. Average 10-day trading volume of 123.63 thousand shares is below the 3-month average of 3.22 million, indicating normal recent market interest.

Arcadia Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.24. This means the shares are trading below this model’s fair value.

Arcadia Biosciences, Inc. trades at a P/E ratio of -0.1, slightly below the S&P 500 average, with a price-to-sales ratio of 0.22 and a price-to-book ratio of 0.32 suggesting the stock is closer to book value. The P/FCF stands at -0.24, also below market averages.

Arcadia Biosciences, Inc. generated EPS of -$3.71 over the past year. Five-year average earnings growth is 50.91%. The latest quarter delivered EPS of -$2.11. The next quarter is forecast at $nan. Next year's EPS is expected at $40.93. Arcadia Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended May 14, 2026, missed forecasts by 163.75%. The prior quarter beat by 48.48%. Over the last six quarters, Apple has recorded several small beats. These include 178.65% in March 20, 2025.

Arcadia Biosciences, Inc. has 1.37 million shares outstanding. The public float is 1.36 million shares, elevated short interest at 1.52% of float. This equals 20.62 thousand shares. The short ratio is 1.47 days. Institutional investors hold 17.08% of the float. Insiders own 0.55%. Mandala Agribusiness Co-Investments I Ltd holds 9.08 million shares, Shupp Darby E has 1.16 million shares and BISHOP TERRI C has 1.16 million shares.

Our AI price prediction model suggests that Arcadia Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -15.62%, with price expected at $0.57 by July 22, 2026, within a range of $0.49 to $0.64 3-Month Outlook: Projected fall of -67.43%, reaching $0.22 by October 06, 2026, with a range of $0.07 to $0.36. 1-Year Outlook: Projected loss of -98.52%, with price at $0.01 by July 08, 2027, within a range of $0.00 to $0.31.

Arcadia Biosciences, Inc. (NASDAQ:RKDA) shares are up 16.16% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Arcadia Biosciences, Inc. trading at a premium to the broader market with a P/E of -0.1. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.12, suggesting 1546.19% upside. Our AI forecast model points to short-term weakness (-15.62% over two weeks), a medium-term fall (-67.43% over three months), and a longer-term loss (-98.52% over one year), with expected trading ranges indicating moderate volatility.